StudyRareStudyRare

Transcobalamin deficiency

Log in to star

Last updated Nov 15, 2026

Log in to add personal notes on this page.

A 3-month-old has pallor, poor feeding, vomiting, and diarrhea and is falling off the weight curve. There are ulcers inside the mouth. Blood counts show pancytopenia with large red cells, and IgG is low. Serum B12 and folate are normal, yet plasma total homocysteine and urine methylmalonic acid are both high.

  • Autosomal recessive; TCN2 (22q12.2), encoding transcobalamin (formerly transcobalamin II); biallelic variants
  • Most variants leave little or no transcobalamin; others make a protein that cannot carry cobalamin into cells
  • Rare: at least 45 affected people have been described
  • No GeneReviews chapter; the intracellular cobalamin chapter covers it as a differential diagnosis

Transcobalamin carries only 10% to 25% of the cobalamin in plasma, but it is the only form cells take up, through the transcobalamin receptor (CD320). Haptocorrin carries the rest and delivers it only to the liver. Without transcobalamin, cobalamin is absorbed and circulates normally on haptocorrin, so serum B12 is usually normal, while the cells are starved of it.

Inside the cell, both B12 coenzymes run short. Methylmalonyl-CoA mutase lacks adenosylcobalamin, so methylmalonic acid rises; methionine synthase lacks methylcobalamin, so total homocysteine rises and methionine falls. Biochemically and clinically, transcobalamin deficiency looks like a combined intracellular defect such as cobalamin C deficiency.

Cells need cobalamin to make DNA and divide, so the disease shows in tissues that divide fast: the bone marrow (megaloblastic anemia, pancytopenia), the lining of the mouth and gut (ulcers, diarrhea), and the immune system.

Treatment aims for very high serum cobalamin: there is some evidence that at such concentrations, some tissues take up cobalamin that is not bound to transcobalamin. That is why the doses are large and frequent.

cubam receptorCUBN, AMN; terminal ileumtranscobalamin and its receptorTCN2, CD320transcobalamin deficiencyLMBD1 and ABCD4 transportersLMBRD1, ABCD4cobalamin on intrinsicfactorcobalamin in the bloodcobalamin in thelysosomecobalamin in thecytosol
Excerpt from cobalamin transport and processing. See the full pathway.

Part of cobalamin transport and processing.

Cobalamin delivery from blood to cells, the step every tissue depends on.

cobalamin absorbed in the ileum → transcobalamin (the block; the carrier cells take up) → transcobalamin receptor (CD320) → lysosome → cytosol → adenosylcobalamin for methylmalonyl-CoA mutase, and methylcobalamin for methionine synthase

  • Accumulates: methylmalonic acid in urine and plasma, and total homocysteine in plasma; serum B12 stays normal because it sits on haptocorrin.
  • Missing: cobalamin inside cells, so both coenzymes; plasma methionine is low or normal, and holotranscobalamin is low.

Onset is in the first months of life: series report admission between 1 and 7 months.

  • Failure to thrive, poor feeding, vomiting and diarrhea
  • Mouth ulcers (stomatitis, mucositis)
  • Megaloblastic anemia or pancytopenia; the marrow can be hypocellular, and the picture can resemble neonatal leukemia
  • Immune deficiency: hypogammaglobulinemia or agammaglobulinemia, lymphopenia, neutropenia, and recurrent infections; it can resemble severe combined immunodeficiency. In one series of six, four had lymphopenia, four neutropenia, and three hypogammaglobulinemia (different presentations of patients with transcobalamin II deficiency, 2019)
  • Neurologic disease: hypotonia and developmental delay at presentation. Myelopathy, stiffness and weakness of the legs (paraparesis), myoclonus, and intellectual disability have been described, and late or inadequate treatment has been followed by severe neurologic and visual impairment
  • Suspect it in an infant with megaloblastic anemia or pancytopenia and high total homocysteine and methylmalonic acid, especially when serum B12 is normal
  • Serum B12 and folate: usually normal, occasionally low, so a normal B12 does not exclude cobalamin deficiency inside cells. Draw total homocysteine, methylmalonic acid, methionine, B12, and folate before the first dose of cobalamin
  • Holotranscobalamin (cobalamin bound to transcobalamin) is low, though few laboratories measure it. Transcobalamin protein by immunoassay is usually reduced, as is the unsaturated B12 binding capacity before treatment
  • Confirm with TCN2 sequencing, or by measuring transcobalamin synthesis in cultured fibroblasts
  • Newborn screening does not target it reliably; a retrospective look at newborn blood spots found a raised C3/C2 ratio in two samples from a series of five patients
Transcobalamin deficiencyImerslund-Gräsbeck syndrome, intrinsic factor deficiencyCobalamin C deficiency
DefectDelivery from blood to cellsAbsorption in the ileum or stomachProcessing inside the cell
Serum B12Usually normalLowNormal
Methylmalonic acid, homocysteineBoth highBoth highBoth high
Usual onsetFirst months of lifeEarly childhoodInfancy, though any age
Extra clueMouth ulcers, immune deficiencyProteinuria in Imerslund-Gräsbeck syndromeMaculopathy and retinopathy

Dietary or maternal B12 deficiency also raises both metabolites in an infant, with low B12 in infant and mother. An infant with pancytopenia and low immunoglobulins can be worked up for leukemia or severe combined immunodeficiency before anyone measures homocysteine.

  • Parenteral cobalamin, frequent and lifelong. In a 30-patient series, current practice favored intramuscular hydroxocobalamin or cyanocobalamin; most patients needed at least 1 mg intramuscularly every week, doses were adjusted to blood counts, total homocysteine, and plasma and urine methylmalonic acid, and continuing injections into adulthood appeared beneficial (update on transcobalamin deficiency: clinical presentation, treatment and outcome, 2014)
  • Start early and do not taper down. Three patients treated early did well at first, while two treated inadequately developed severe neurologic and visual impairment later (should transcobalamin deficiency be treated aggressively, 2010). In another series, blood counts fell whenever the dose was reduced or stopped, and every child had speech and walking delay at reassessment at 2 to 4 years (seven patients with transcobalamin deficiency, 2017). Weekly 1 mg injections corrected the blood counts but did not secure normal development
  • Blood counts respond: hematologic abnormalities resolved on parenteral cobalamin in every child of the six-patient series
  • Follow-up: blood counts, total homocysteine, methylmalonic acid, growth, and development. Include eye examinations: one patient treated continuously from 4 months developed subclinical retinopathy and maculopathy on electroretinography over 10 years (subclinical maculopathy and retinopathy in transcobalamin deficiency, 2022)
  • Recurrence risk 25% for each pregnancy of carrier parents; test a newborn sibling promptly, since outcome depends on starting treatment early

Full tank, empty engine: serum B12 is normal because the blood still holds the vitamin on haptocorrin; the cells run dry because transcobalamin is the only carrier they take up.

Reference Links